Loading data for RLAY — first visit, this takes a few seconds.

알림

Relay Therapeutics Inc. (RLAY)

NasdaqGM: RLAY · 실시간 가격 · USD

20.74

+0.13 (0.63%)

종가 기준: Aug 19, 2026, 8:00 PM

21.43

+3.30%

프리마켓: 4:00 AM

0.63% (1D)

데이터 없음

매수호가	14.35
시가총액	4.54B
매출 (ttm)	10.35M
순이익 (ttm)	-286.04M
베타	1.70
EPS (ttm)	-1.57
P/E (ttm)	n/a
선행 P/E	-12.59
P/B (ttm)	5.09
P/S (ttm)	439.13
Earnings Date	Nov 5, 2026

매도호가	24.83
거래량	2,069,846
평균 거래량 (20일)	3,521,009
시가	21.05
전일 종가	20.61
일중 범위	20.45 - 21.27
52주 범위	3.31 - 21.27
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

RLAY 소개

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jul 16, 2020

직원 수 202

상장 거래소 NasdaqGM

티커 RLAY

웹사이트 https://www.relaytx.com

전체 기업 정보

재무 실적

2025년 Relay Therapeutics의 매출은 15.36M로, 전년 10.01M 대비 53.44% 증가했습니다. 순이익은 -276.48M로, -18.13% 감소했습니다.

재무제표

어닝 서프라이즈

Relay Therapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $350K 예상치 하회 $0, 및 -48.30% 전년 대비 감소.

EPS -0.41 예상치 하회 -0.02, 및 0.00% 전년 대비 성장.

다음 실적 발표

Relay Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2일 전 · Zacks

The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci

AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.

2일 전 · Zacks

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

6일 전 · Barchart

Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year

Relay Therapeutics (RLAY) is a clinical-stage precision medicines company focused on targeted oncology, with a $4.4 billion market cap. RLAY has surged 486% over the past year. Shares are trading near...

1주 전 · Zacks

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 0.00% and -86.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2주 전 · Zacks

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +33.33% and -5.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 페이지 중 1

Relay Therapeutics Inc. (RLAY)